At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed adenocarcinoma of the pancreas with evidence of metastatic disease
- ✓Measurable disease ≥20 mm with conventional techniques or ≥10 mm with spiral CT scan
- ✓Documented progression with measurable metastatic disease from prior therapy (adjuvant, locally advanced, or 1 prior metastatic regimen)
- ✓Karnofsky performance status 80-100% OR ECOG performance status 0-1
- ✕Brain metastases documented
- ✕Peripheral neuropathy grade >1
- ✕Uncontrolled diabetes
- ✕Uncontrolled intercurrent illness including ongoing/active infection, symptomatic CHF, unstable angina, cardiac arrhythmia or MI within 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Non-Randomized Phase II Study of Alvocidib (Flavopiridol) in Combination With Docetaxel in Refractory, Metastatic Pancreatic Cancer (NCI #6366)
In Brief
A Phase 2 clinical trial evaluating alvocidib and docetaxel for Adenocarcinoma of the Pancreas and 2 related conditions. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Drugs used in chemotherapy, such as docetaxel and flavopiridol, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Flavopiridol may also help docetaxel work better by making tumor cells more sensitive to the drug. This phase II trial is studying how well giving docetaxel followed by flavopiridol works in treating patients with refractory metastatic pancreatic cancer.
Study Details
Timeline
Interventions
Given IV
Given IV